Company / Gross Profit
Serina Therapeutics, Inc. Gross Profit History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$102.0K
FY2023
5-year range
$21.0K / $125.0K
FY2019-FY2023
Trend
+385.7%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Profit changed +386% YoY in FY2023, a notable deviation from the 4-year average annual change of +64%.
Based on SEC 10-K filings.
$102,000 in FY2023 with a 5-year CAGR of -37.1%.
Declined from $125,000 to $102,000 over the past 2 years.
Gross Profit over time
Growth rates
- 3-Year CAGR
- -59.0%
- 5-Year CAGR
- -37.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -37.1%, indicating a declining trend.
- In FY2023, gross profit increased 385.7% year-over-year.
- Peak gross profit was recorded in FY2020.
- Lowest gross profit in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $102.0K | +385.7% |
| FY2022 | $21.0K | -83.2% |
| FY2021 | $125.0K | -91.6% |
| FY2020 | $1.5M | +43.8% |
| FY2018 | $1.0M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026